Table 1.
A summary of pre-clinical nanobody probes being developed for tumor-specific FGS.
| Target | Molecule Name | Fluorophore | Nb Conjugation Approach | Dose nb Administered | Time to Peak nb TBR | Peak nb TBR | Imaging Device | Disease |
|---|---|---|---|---|---|---|---|---|
| EGFR | 7D12 [30] | IRDye 800CW | NHS | 25 ug | 24 h | 2.3′s | IVIS Lumina | Epidermoid carcinoma |
| 7D12 [31] | IRDye 800CW, IRDye680RD | NHS | 75 ug | 24 h | 2, 2.72 at 24 h | FLARE and IVIS spectrum | Head and neck cancer | |
| Her 2 | 11A4 [32] | IRDye 800CW | Site directed cysteine-maleimide and randomly labeled | 50 ug | 4 h | 2.5–3 | IVIS Spectrum | Breast cancer |
| 2Rs15d [33] | IRDye 800CW | Site directed cysteine-maleimide | 2 nmol | 3 h | 14.4–42 | Fluobeam800 | Ovarian cancer | |
| 2Rs15d [34] | IRDye 800CW, IRDye680RD | Site directed cysteine-maleimide and randomly labeled | 2 nmol | 3 h | 6.6 at 3 h, 12 at 24 h | Fluobeam800, FMT2500 Perkin Elmer | Ovarian cancer, breast cancer | |
| CEA | NbCEA5 [35] | IRDye 800CW | Site directed cysteine-maleimide | 2 nmol | 2 h | 2.6 | MaestroCRI, Firefly, StrykerAIM | Pancreatic cancer |
| CAIX | B9 [36] | IRDye800CW | Site directed cysteine-maleimide | 50 ug | 2–4 h | 4.3 | SurgOptix | Breast cancer, pre-invasive breast cancer |
| CAIX & Her2 | B9, 11A4 [37] | IRDye800CW, IRDye680RD or IRDye700DX | Site directed cysteine-maleimide | 50 ug each of each probe, 100 ug per mouse | 2–6 h | 2–3.3 | IVIS Spectrum | Breast cancer |